Eric Vigneault

Quebec, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Pelvic nodes ultra-hypo fractionated versus conventionally fractionated IMRT with HDR brachytherapy in prostate cancer: interim analysis of a collaborative multi-institutional non-inferiority phase 3 trial (PCS-XI, NCT05820633).

Pelvic nodes ultra-hypo fractionated versus conventionally fractionated IMRT with HDR brachytherapy in prostate cancer: interim analysis of a collaborative multi-institutional non-inferiority phase 3 trial (PCS-XI, NCT05820633).

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: March 08, 2026

Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.

Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.

Journal: Endocrine oncology (Bristol, England)

Published: December 09, 2025

Reply by Authors.

Reply by Authors.

Journal: The Journal of urology

Published: September 10, 2025

2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update).

2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update).

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Published: August 06, 2025

A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study.

A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study.

Journal: The Journal of urology

Published: July 25, 2025

Impact of Persistent Hypogonadism on Overall Survival After Androgen Deprivation Therapy in Localized Prostate Cancer Patients: Long-Term Prospective Data.

Impact of Persistent Hypogonadism on Overall Survival After Androgen Deprivation Therapy in Localized Prostate Cancer Patients: Long-Term Prospective Data.

Journal: International journal of radiation oncology, biology, physics

Published: June 04, 2025

Retrospective evaluation of high-dose-rate brachytherapy multicriteria planning using physical dose versus radiobiological criteria for prostate cancer.

Retrospective evaluation of high-dose-rate brachytherapy multicriteria planning using physical dose versus radiobiological criteria for prostate cancer.

Journal: Scientific reports

Published: May 21, 2025

2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castration-sensitive prostate cancer (Update).

2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castration-sensitive prostate cancer (Update).

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Published: May 21, 2025

The Canadian brachytherapy experience: Results of the Canadian brachytherapy group national survey.

The Canadian brachytherapy experience: Results of the Canadian brachytherapy group national survey.

Journal: Brachytherapy

Published: May 16, 2025

Platform for the Evaluation of innovations in Radiation oncology through registry-based conduct of multi-centric pragmatic randomized trials: PERa implementation.

Platform for the Evaluation of innovations in Radiation oncology through registry-based conduct of multi-centric pragmatic randomized trials: PERa implementation.

Journal: Trials

Published: March 16, 2025

Clinical implementation of an open-source Monte Carlo system across multiple centers for permanent implant brachytherapy dose evaluation.

Clinical implementation of an open-source Monte Carlo system across multiple centers for permanent implant brachytherapy dose evaluation.

Journal: Brachytherapy

Published: January 28, 2025

Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377.

Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377.

Journal: International journal of radiation oncology, biology, physics

Published: September 25, 2024

Showing 1-12 of 44

Last Updated: 09/26/2026